Table 1.
Registered Current Clinical Trials of small plant-derived molecules radiosensitizers (https://Clinicaltrials.gov/, accessed on 4 August 2022).
| Identifier | Natural Compound | Tumor Type | No. of Patients | Phase of Clinical Trials | Drug Used in Combination with Radiotherapy |
|---|---|---|---|---|---|
| NCT03824327 | Papaverine | Non-Small Cell Lung Cancer or Lung Metastases | 24 | Phase I | Papaverine |
| NCT05136846 | Papaverine and Paclitaxel | Locally Advanced Non-Small Cell Lung Cancer | 28 | Phase I | Carboplatin + Paclitaxel + Durvalumab and Papaverine |
| NCT02459457 | Paclitaxel | Local Advanced Esophageal Cancer | 321 | Phase III | Group 1: Paclitaxel + Cisplatin Group 2: Paclitaxel + Fluorouracil Group 3: Paclitaxel + Carboplatin |
| NCT01591135 | Paclitaxel | Locally Advanced Esophageal Carcinoma | 436 | Phase III | Group 1: Paclitaxel + 5-fluorouracil Group 2: Cisplatin + 5-fluorouracil |
| NCT02280252 | Paclitaxel | Breast Cancer | 69 | Phase II | Paclitaxel |
| NCT00238420 | Paclitaxel | Bladder Cancer | 70 | Phase I/II | Paclitaxel + Trastuzumab |
| NCT00231868 | Paclitaxel | Uterine Cancer | 81 | Phase II | Carboplatin + Paclitaxel |
| NCT00003591 | Paclitaxel | Pancreatic Cancer | 122 | Phase II | Paclitaxel |
| NCT02724618 | Curcumin | Prostate Cancer | 64 | Phase II | Nanocurcumin |
| NCT01917890 | Curcumin | Prostate Cancer | 40 | Completed | Curcumin |
| NCT00745134 | Curcumin | Rectal Cancer | 45 | Phase II | Capecitabine + Curcumin |
| NCT04294836 | Curcumin | Cervical Cancer | 240 | Phase II | Cisplatin + Curcumin |
| NCT02075112 | Genistein | Advanced Squamous Cell Carcinoma of the Head and Neck | 24 | Phase I | Soy isoflavone + Cisplatin |
| NCT00769990 | Genistein | Bone Metastases | 0 | Phase I/II | Genistein |